RxDoctor Payments Data

Praveen Modi, MD

Internal Medicine · Plymouth, MINPI 1144285669

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 66 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$222
  • Amgen$122
  • AstraZeneca$100
  • Exact Sciences$98
  • Boehringer Ingelheim$95
  • Novo Nordisk$73
  • plus $457 from 13 others

What the payments were for

  • Food & beverage$1,11095%
  • Education$555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,166 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$322,177
Medicare patients
340
Services billed
7,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$283,728
MounjaroTirzepatide134$138,167
TrulicityDulaglutide76$136,475
JardianceEmpagliflozin91$104,757
OzempicSemaglutide43$68,302
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$57,109
JanuviaSitagliptin Phosphate60$50,243
XareltoRivaroxaban43$50,216
JanumetSitagliptin Phos/Metformin Hcl26$27,434
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$25,737
MyrbetriqMirabegron24$16,193
TradjentaLinagliptin11$14,934
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$13,860
Repatha SyringeEvolocumab22$12,705
Atorvastatin Calcium1,008$12,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$53$292,072262 claims
Lilly USA, LLCMounjaro, Trulicity$60$274,642210 claims
Boehringer IngelheimJardiance, Tradjenta$95$119,691102 claims
MerckJanuvia, Janumet$41$77,67786 claims
GSKTrelegy Ellipta, Shingrix$59$68,43689 claims
Novo NordiskOzempic$73$68,30243 claims
Johnson & JohnsonXarelto$222$50,21643 claims
Astellas Pharma US IncMyrbetriq$31$16,19324 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$7,452578 claims
AstraZenecaSymbicort$100$5,31211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Plymouth

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →